- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02833194
Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome (NOHA-PSY)
June 5, 2023 updated by: Centre Hospitalier Universitaire de Nīmes
The primary objective of this study was to evaluate and compare the prevalence of the following psychiatric pathologies (based on the MINI5.0.0 questionnaire) among 3 groups of women (Leiden versus aP1Ab-positive versus thrombophilia-negative) with similar obstetrical histories 10 years after their initial assessment/diagnosis.
- Mood disorders, including depressive episodes during the previous two weeks, recurrent depressive disorders at any point in life, dysthymia in the last two years, or any current or past manic episode;
- Anxiety disorders, including current agoraphobia, current panic disorders, agoraphobia with panic disorders, current social phobia, generalized anxiety in the last 6 months, or current posttraumatic stress syndrome;
- Apparent psychotic syndromes, including isolated or recurrent psychotic syndromes, past or present (clinically validated),
- Current alcohol or drug problems (dependence or abuse).
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
1592
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nîmes Cedex 09, France, 30029
- CHU de Nimes - Hopital Universitaire Caremeau
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients were selected via the regional NOHA (Nîmes Obstetricians and Hematologists - Antiphospholipid Syndrome study) network, which referred women with losses of spontaneous pregnancies to the Hematology Outpatient Department of the Nîmes University Hospital.
Description
Inclusion Criteria:
- Three unexplained consecutive spontaneous abortions before the 10th week of gestation (the recurrent embryo loss subgroup) - OR -
- One unexplained death of a morphologically normal fetus (fetal loss) at or after the 10th week of gestation (fetal loss subgroup).
Exclusion Criteria:
- Any history of thrombotic events or any treatment given during previous pregnancies that might have modified the natural course of the condition
- Women whose pregnancy losses could be explained by infectious, metabolic, anatomic or hormonal facotrs, or associated with paternal or maternal chromosomal causes
- Seropositivity for HIV, hepatitis B or C
- Women with antithrombin, protein C, or protein S deficiency, and women with abnormal fibrinogen or with the JAK2 V617F mutation were further excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Leiden Group
Women with an isolated F5 rs6025 polymorphism or an isolated F2 rs1799963 polymorphism.
|
aP1Ab-positive
Inclusion in the "aP1Ab" Group:
|
Thrombophilia-negative
Women with completely negative thombophilia screening results.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mini Internationl Neuropsychiatric Interview 5.0.0
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jean-Christophe Gris, MD, PhD, Centre Hospitalier Universitaire de Nîmes
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2005
Primary Completion (Actual)
July 1, 2015
Study Completion (Actual)
July 1, 2015
Study Registration Dates
First Submitted
July 12, 2016
First Submitted That Met QC Criteria
July 12, 2016
First Posted (Estimated)
July 14, 2016
Study Record Updates
Last Update Posted (Actual)
June 6, 2023
Last Update Submitted That Met QC Criteria
June 5, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOCAL/2015/JCG-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antiphospholipid Syndrome
-
Cairo UniversityCompletedPrimary Antiphospholipid SyndromeEgypt
-
University of FloridaHoffmann-La RocheCompletedAntiphospholipid Antibody SyndromeUnited States
-
Hospital Universitario Pedro ErnestoCompletedAntiphospholipid Antibody Syndrome
-
Italian Society for RheumatologyRecruitingAntiphospholipid Syndrome | Seronegative Antiphospholipid SyndromeItaly
-
Duke UniversityRecruitingAntiphospholipid SyndromeUnited States
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Hospital for...Active, not recruitingAntiphospholipid Syndrome (APS)United States
-
Richard Burt, MDWithdrawnANTIPHOSPHOLIPID SYNDROMEUnited States
-
Ruijin HospitalRecruitingAntiphospholipid Syndrome (APS)China
-
University Hospital, RouenUnknownAntiphospholipid Syndrome (APS)France
-
University Hospital, AngersUnknownPrimary Antiphospholipid SyndromeFrance